New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists

Foxx‐Orenstein, Amy E.

doi:10.1177/1756283x16633050

Cited by 37 publications

(39 citation statements)

References 163 publications

(232 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Treatment of IBS is important because symptoms cause significant impairment of health-related In addition, a significantly higher percentage of patients receiving Rifaximin had adequate relief from IBS-related bloating in the first 4 weeks after the 2-week treatment phase compared with placebo (40.2% versus 30.3 %, Respectively, p < 0.001). The results of these studies confirm that Rifaximin has a sustained effect in patients with IBS-D, with a 2-week treatment cycle providing patients with a relief for at least 3 months [23]. In addition, three meta-analyzes of which may reflect differences in the underlying cause of symptoms.…”

Section: Discussionsupporting

confidence: 63%

Assessment of the Efficacy of Rifaximin in the Management of Irritable Bowel Syndrome (IBS)

Doffou¹,

Anzouan-Kacou²,

Messou³

et al. 2017

OJGas

View full text Add to dashboard Cite

The aim of our study was to assess in our context, the efficacy of Rifaxim in improving the symptoms of irritable bowel syndrome particularly in its diarrheal (IBS-D) or mixed (IBS-DC) component and therefore assess its impact on patients' quality of life. Patients and methods: This was an uncontrolled, non-comparative prospective cohort study of a single group of patients. Patients recruitment was done in two University Hospitals for 6 months (September 2015-February 2016. Were included ambulatory patients, male or female, aged 18 -75 years, with diarrheic IBS (IBS-D) or mixed IBS (IBS-DC) diagnosed according to Rome III criteria and who agreed to participate in the study. Each patient received 400mg Rifaximin × 2/d for 15 days. The overall assessment of the efficacy of treatment at D15 (end of treatment) and D30 (2 weeks post-treatment) was the primary criterion of judgment. The statistical tests used were the Chi-square test and Fisher's exact test for the qualitative variables and Student's test for the quantitative variables. Results: A total number of 30 patients (16 women) with an average age of 44.5 ± 13.9 years were included. The overall assessment of symptoms by the patient with the Likert scale found 28 (93.3%) patients, 12 (40%) patients and 10 patients (33.3%) for a scale ≥2 at D0, D15 and D30 respectively. The assessment of the intensity of pain or abdominal discomfort found at D0, D15 and D30 respectively: 27(90%), 13(43.4%) and 6(20.1%) patients who had an EVA score > 2. The mean score for Francis to assess the improved quality of life was 247.1 ± 97.4 at D0, 99.8 ± 63.1 at D15 and 128.8 ± 70.6 at D30. Conclusion: There is a good overall improvement of symptoms in our patients suffering from IBS-D or mixed (IBS-DC) on Rifaximin with improvement of the quality of life.

show abstract

Section: Discussionsupporting

confidence: 63%

Assessment of the Efficacy of Rifaximin in the Management of Irritable Bowel Syndrome (IBS)

Doffou¹,

Anzouan-Kacou²,

Messou³

et al. 2017

OJGas

View full text Add to dashboard Cite

show abstract

“…FGIDs include functional dyspepsia (FD) and irritable bowel syndrome (IBS), affecting an estimated 3–28% of the global population [108], particularly the elderly and women, and may severely affect the individual’s quality of life and wellbeing [107, 109]. Upper gastrointestinal disorders include gastric reflux, stomach ache, delayed gastric emptying, nausea and vomiting, and lower gastrointestinal disorders include constipation, indigestion, bloating and diarrhoea.…”

Section: Digestive Healthmentioning

confidence: 99%

The nutritional and health attributes of kiwifruit: a review

Richardson¹,

Ansell

Drummond³

2018

Eur J Nutr

247

161

View full text Add to dashboard Cite

PurposeTo describe the nutritional and health attributes of kiwifruit and the benefits relating to improved nutritional status, digestive, immune and metabolic health. The review includes a brief history of green and gold varieties of kiwifruit from an ornamental curiosity from China in the 19th century to a crop of international economic importance in the 21st century; comparative data on their nutritional composition, particularly the high and distinctive amount of vitamin C; and an update on the latest available scientific evidence from well-designed and executed human studies on the multiple beneficial physiological effects.Of particular interest are the digestive benefits for healthy individuals as well as for those with constipation and other gastrointestinal disorders, including symptoms of irritable bowel syndrome. The mechanisms of action behind the gastrointestinal effects, such as changes in faecal (stool) consistency, decrease in transit time and reduction of abdominal discomfort, relate to the water retention capacity of kiwifruit fibre, favourable changes in the human colonic microbial community and primary metabolites, as well as the naturally present proteolytic enzyme actinidin, which aids protein digestion both in the stomach and the small intestine. The effects of kiwifruit on metabolic markers of cardiovascular disease and diabetes are also investigated, including studies on glucose and insulin balance, bodyweight maintenance and energy homeostasis.ConclusionsThe increased research data and growing consumer awareness of the health benefits of kiwifruit provide logical motivation for their regular consumption as part of a balanced diet. Kiwifruit should be considered as part of a natural and effective dietary strategy to tackle some of the major health and wellness concerns around the world.

show abstract

“…Additional common conditions that patients may present with to a chiropractic office and that are known to be promoted by chronic endotoxemia include chronic fatigue, anxiety, impaired cognition, migraine headache, impaired sleep, interstitial cystitis, type 2 diabetes, atherosclerosis, hypertension, general feeling of ill health, and widespread pain that may be diagnosed as fibromyalgia 31, 32, 47, 48, 49, 50, 51, 52, 53, 54, 55, 56, 57, 58, 59, 60, 61, 62. Bacterial endotoxemia is also associated with childhood obesity and may be a key contributor to type 2 diabetes and cardiovascular disease later in life 63 …”

Section: Bacterial Endotoxin In Relation To Chiropractic Practicementioning

confidence: 99%

“…Third, patients who suffer from postprandial abdominal bloating that occurs within 1 hour of eating could be considered “toxic.” In the absence of gluten sensitivity, celiac disease, or other gastrointestinal tract pathologic conditions, the most common cause of such bloating is the fermentation of consumed carbohydrates by an overgrown small intestine bacterial population,32, 49 which leads to endotoxemia 35, 36. Postprandial bloating is an almost universal symptom in patients with irritable bowel syndrome 32 .…”

Section: Measuring Bacterial Endotoxin Levelsmentioning

confidence: 99%

Toxins, Toxicity, and Endotoxemia: A Historical and Clinical Perspective for Chiropractors

Seaman

2016

Journal of Chiropractic Humanities

View full text Add to dashboard Cite

ObjectiveThe purpose of this commentary is to review the notion of toxicity in the context of chiropractic practice.DiscussionThe belief that body toxicity is the cause of disease has been promoted for thousands of years. Prior to the emergence of the chiropractic profession, the medical profession embraced the notion that the body becomes “toxic,” requiring detoxification interventions or surgery. The legacy of body toxicity within the chiropractic approach to patient care began with Daniel David Palmer. Today, some sectors within the medical and chiropractic professions continue to embrace the concept of body toxicity and the related need to engage in detoxifying treatments. The most common areas of focus for detoxification are the intestines and liver; however, the nature of the toxicity in these organs has yet to be defined or measured. In contrast, diet-induced systemic bacterial endotoxemia is a measureable state that is known to be promoted by a diet rich in sugar, flour, and refined oil. This suggests that bacterial endotoxin may be a candidate toxin to consider in the clinical context, as many common conditions, such as obesity, metabolic syndrome, diabetes, interstitial cystitis, depression, and migraine headache, are known to be promoted by endotoxemia.ConclusionA diet rich in refined sugar, flour, and oils may induce proinflammatory changes within intestinal microbiota that lead to systemic, low-grade endotoxemia, which is a common variety of “toxicity” that is measurable and worthy of research consideration. Introducing a diet to reduce endotoxemia, rather than attempting to target a specific organ, appears to be a rational clinical approach for addressing the issue of toxicity.

show abstract

New and emerging therapies for the treatment of irritable bowel syndrome: an update for gastroenterologists

Abstract: Irritable bowel syndrome is a functional bowel disorder with gastrointestinal symptoms (e.g. abdominal pain, straining, urgency, incomplete evacuation, nausea, and bloating) that occur alongside bowel function alterations (i.e.

Cited by 37 publications

References 163 publications

Assessment of the Efficacy of Rifaximin in the Management of Irritable Bowel Syndrome (IBS)

Assessment of the Efficacy of Rifaximin in the Management of Irritable Bowel Syndrome (IBS)

The nutritional and health attributes of kiwifruit: a review

Toxins, Toxicity, and Endotoxemia: A Historical and Clinical Perspective for Chiropractors

Contact Info

Product

Resources

About